Joseph Barsuglia

Clinical and research psychologist specializing in psychedelic medicine and alternative healthcare

Data updated

Papers

11 publications

Trials

0 clinical trials

Research Footprint

Joseph Barsuglia appears in 11 tracked papers (2017–2026), most studied alongside Ibogaine, 5-MeO-DMT and Psilocybin, across Substance Use Disorders (SUD), Anxiety Disorders and Depressive Disorders.

Most-cited paper: 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety (139 citations).

Frequent co-authors: Alan Davis, Martin Polanco and Rafaelle Lancelotta.

Background & Research

Joseph P. Barsuglia is a clinical researcher working at the intersection of psychedelic medicine and addiction/psychiatric care. His recent contributions emphasise pragmatic, real‑world investigations—ranging from longitudinal case studies of 5‑MeO‑DMT for post‑traumatic stress disorder and suicidality to naturalistic group‑setting evaluations that report unintended improvements in anxiety and depression. Barsuglia has also contributed to case reports and SPECT imaging studies that examine sequential administration strategies combining ibogaine and 5‑MeO‑DMT for alcohol use disorder, and he has authored mixed‑method analyses of persisting effects following ibogaine detoxification.

Affiliations

Institutions, companies, and organisations Joseph Barsuglia is associated with.